Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix® or MMR-II®

This publication has 17 references indexed in Scilit:

• Public opponents of vaccination: a case study
  Vaccine, 2003
• Unintended events following immunization with MMR: a systematic review
  Vaccine, 2003
• A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children
  International Journal of Infectious Diseases, 2002
• Vaccine safety: risk communication — a global perspective
  Vaccine, 2001
• Vaccine safety — improving monitoring
  Vaccine, 2001
• Making vaccines more acceptable — methods to prevent and minimize pain and other common adverse events associated with vaccines
  Vaccine, 2001
• The seroepidemiology of measles in Western Europe
  Epidemiology and Infection, 2001
• Immunogenicity and Reactogenicity of a New Measles, Mumps and Rubella Vaccine When Administered as a Second Dose at 12 y of Age
  Scandinavian Journal of Infectious Diseases, 2001
• Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response
  The Journal of Pediatrics, 2000
• Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children
  The Pediatric Infectious Disease Journal, 1999